Berkeley Heights, NJ, July 24, 2003
The conference call can be accessed as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta
Incorporated.
International: Dial (706) 679-3140, reference Genta
Incorporated.
A replay will be available two hours after the completion of the
conference call and archived through Saturday, August 30, 2003 for
30 days, accessible as follows:
U.S./Canada: Dial (800) 642-1687, enter 1654967 for
conference ID.
International: Dial (706) 645-9291, enter 1654967 for
conference ID.
The webcast will be available in the Investor Relations section
of the Company's website at:
http://audioevent.mshow.com/117620/
and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA/DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company' lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing.
The leading drug in Genta's small molecule program is Ganite
TM
(gallium nitrate injection), which the Company intends to launch
later this year for treatment of cancer-related hypercalcemia that
is resistant to hydration. For more information about Genta,
please visit our website at:
http://www.genta.com/
.
This press release and the conference call and webcast to
follow contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company' Annual
Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
